Polyrizon Ltd. (PLRZ)

Polyrizon Ltd. is an Israeli biotechnology company developing nasal sprays designed to form a protective barrier inside the nasal cavity. Its products are based on proprietary hydrogel technology that, once sprayed, creates a thin layer intended to capture and contain allergens, viruses and other airborne particles before they reach the nasal tissue.

The company's lead programs target protection against allergens and respiratory pathogens, and it has also explored using its hydrogel platform as a delivery vehicle for intranasal drugs, which could allow medicines to remain at the site of application longer. Polyrizon's candidates are generally pursued under medical device regulatory pathways rather than as conventional drugs.

Polyrizon completed its initial public offering in 2024, and its ordinary shares trade on the Nasdaq market under the ticker PLRZ.